HR 7352119th CongressIn Committee

PASTEUR Act of 2026

Standard Summary
Balanced plain-English summary

The PASTEUR Act of 2026 amends the Public Health Service Act to create a subscription-style contract program that incentivizes development of innovative antimicrobial drugs targeting serious and urgent resistant pathogens. It establishes scoring criteria, advisory group oversight, annual payments, stewardship grants, surveillance requirements, and $6 billion in appropriated funding.

Key Points

  • 1Creates U.S. Novel Antimicrobial Supply Contracts with annual payments ranging from $75 million to $300 million.
  • 2Establishes a Critical Need Antimicrobial Advisory Group and a scoring system for eligible antimicrobial drugs.
  • 3Funds hospital and outpatient antimicrobial stewardship programs and expands surveillance of resistance and use.
  • 4Appropriates $6 billion for fiscal year 2026 to carry out the program.

Impact Areas

Patients with drug-resistant infectionsHospitals and health care facilitiesAntimicrobial drug developers and manufacturersPublic health surveillance systemsFederal health agencies and Medicare/Medicaid programs
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026